Fig. 5: Long-term rFGF4 treatment improves glucose intolerance and insulin resistance in diabetic mice.

a, b Blood glucose (a) and body weight (b) of ad libitum-fed db/db mice injected with rFGF4 (1.0 mg/kg body weight) (n = 8) on alternate days for 37 days with PBS buffer (db/db) (n = 8); db/m mice served as controls (n = 14). c, d Blood glucose (c) and body weight (d) of ad libitum-fed DIO mice injected with rFGF4 (1.0 mg/kg body weight) on alternate days for 15 days with PBS buffer (DIO) as controls (n = 5). e Left: OGTT over the course of 120 min done following 37 days of chronic administration of rFGF4 (1.0 mg/kg body weight) to db/db mice (n = 5). Right: integrated AUC for changes in blood glucose levels. f Left: OGTT over the course of 120 min done following 15 days of chronic administration of rFGF4 (1.0 mg/kg body weight) to DIO mice (n = 6). Right: integrated AUC for changes in blood glucose levels. g, h Blood glucose levels (g) and glucose infusion rate (GIR) (h) during a hyperinsulinemic euglycemic clamp for 14 days in rFGF4-treated (1.0 mg/kg body weight) db/db mice (n = 6) with PBS buffer (db/db) served as controls (n = 7). i–k Glucose infusion rate (GIR) (i), glucose disposal rate (GDR) (j), and insulin stimulated glucose disposal rate (IS-GDR) (k) during a hyperinsulinemic euglycemic clamp for 14 days in rFGF4-treated (1.0 mg/kg body weight) DIO mice (n = 5) with PBS buffer (DIO) served as controls (n = 7). Data are presented as mean +/− SEM. Statistical comparisons in (a, c, e (left penal) and f (left penal)) are two-way ANOVA tests with Tukey’s multiple comparisons tests (a and e) or Šídák’s multiple comparisons tests (c, f and h). Statistical comparison in (e (right penal) is one-way ANOVA test with Tukey’s multiple comparisons test. Statistical comparisons in (f (right penal) and i–k) are unpaired two-tailed tests. Source data are provided as a Source data file.